In 1998, a clinical classification of pulmonary hypertension (PH) was established, categorizing PH into groups which share similar pathological and hemodynamic characteristics and therapeutic approaches. During the 5th World Symposium held in Nice, France, in 2013, the consensus was reached to maintain the general scheme of previous clinical classifications. However, modifications and updates especially for Group 1 patients (pulmonary arterial hypertension [PAH]) were proposed. The main change was to withdraw persistent pulmonary hypertension of the newborn (PPHN) from Group 1 because this entity carries more differences than similarities with other PAH subgroups. In the current classification, PPHN is now designated number 1. Pulmonary hypertension associated with chronic hemolytic anemia has been moved from Group 1 PAH to Group 5, unclear/multifactorial mechanism. In addition, it was decided to add specific items related to pediatric pulmonary hypertension in order to create a comprehensive, common classification for both adults and children. Therefore, congenital or acquired left-heart inflow/outflow obstructive lesions and congenital cardiomyopathies have been added to Group 2, and segmental pulmonary hypertension has been added to Group 5. Last, there were no changes for Groups 2, 3, and 4. © 2013 by the American College of Cardiology Foundation. Published by Elsevier Inc.
cited By (since 1996)1
Ga Simonneau, Gatzoulis, M. Ab, Adatia, Ic, Celermajer, Dd, Denton, Ce, Ghofrani, Af, Sanchez, M. AgGomez, Kumar, RhKrishna, Landzberg, Mi, Machado, R. Fj, Olschewski, Hk, Robbins, I. Ml, and Souza, Rm, “Updated clinical classification of pulmonary hypertension”, Journal of the American College of Cardiology, vol. 62, pp. D34-D41, 2013.